PDE4A and atopic eczema: Indeed, previous studies have shown that the inhibition of phosphodiesterase 4 (PDE4), a cAMP-degrading enzyme, improves atopic dermatitis and psoriasis50,51; consequently, certain PDE4 inhibitors have been approved to treat these diseases52,53.